Tonix Pharmaceuticals (TNXP) Stock Price, News & Analysis

Company Overview

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

Key Stats

• Today's Range: $35.66 to $39.60
• 50-Day Range: $28.93 to $49.72
• 52-Week Range: $6.76 to $130.00
• Volume: 1.27 million shs
• Average Volume: 1.31 million shs
• Market Capitalization: $287.11 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $70.00
• Consensus Rating: Buy

Tonix Pharmaceuticals Stock Analysis - MarketRank™

Tonix Pharmaceuticals scored higher than 68% of companies evaluated by MarketBeat, and ranked 397th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Tonix Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Tonix Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Tonix Pharmaceuticals are expected to grow in the coming year, from ($1,762.50) to ($541.50) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Tonix Pharmaceuticals is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Tonix Pharmaceuticals is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Tonix Pharmaceuticals has a P/B Ratio of 1.22. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

16.19% of the float of Tonix Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Tonix Pharmaceuticals has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Tonix Pharmaceuticals has recently decreased by 1.65%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Tonix Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Tonix Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

16.19% of the float of Tonix Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Tonix Pharmaceuticals has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Tonix Pharmaceuticals has recently decreased by 1.65%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.8 / 5
• News Sentiment: 0.85

News Sentiment

Tonix Pharmaceuticals has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Tonix Pharmaceuticals this week, compared to 5 articles on an average week.

Search Interest

69 people have searched for TNXP on MarketBeat in the last 30 days. This is an increase of 28% compared to the previous 30 days.

MarketBeat Follows

46 people have added Tonix Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 59% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Tonix Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $86,200.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 0.03% of the stock of Tonix Pharmaceuticals is held by insiders.

Percentage Held by Institutions

82.26% of the stock of Tonix Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

TNXP Stock Analysis - Frequently Asked Questions

How have TNXP shares performed this year?

Tonix Pharmaceuticals' stock was trading at $32.98 at the beginning of the year. Since then, TNXP stock has increased by 17.4% and is now trading at $38.7050.

How were Tonix Pharmaceuticals' earnings last quarter?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) issued its quarterly earnings results on Monday, May, 12th. The company reported ($2.84) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($3.23) by $0.39. The company earned $2.43 million during the quarter, compared to the consensus estimate of $2.55 million. Tonix Pharmaceuticals had a negative net margin of 1,313.87% and a negative trailing twelve-month return on equity of 120.96%.

When did Tonix Pharmaceuticals' stock split?

Shares of Tonix Pharmaceuticals reverse split on Wednesday, February 5th 2025.The 1-100 reverse split was announced on Monday, February 3rd 2025. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 4th 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

How do I buy shares of Tonix Pharmaceuticals?

Shares of TNXP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Tonix Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Tonix Pharmaceuticals investors own include Meta Platforms (META), Digital Turbine (APPS), NIO (NIO), Sorrento Therapeutics (SRNE) and Vaxart (VXRT).

Company Calendar

• Last Earnings: 5/12/2025
• Today: 8/01/2025
• Next Earnings (Estimated): 8/15/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TNXP
• CIK: 1430306
• Web: www.tonixpharma.com
• Phone: (862) 799-8599
• Fax: 212-923-5700
• Employees: 50
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Tonix Pharmaceuticals: $70.00
• High Price Target: $70.00
• Low Price Target: $70.00
• Potential Upside/Downside: +87.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1,963.61)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$130.04 million
• Net Margins: -1,313.87%
• Pretax Margin: -1,313.87%
• Return on Equity: -120.96%
• Return on Assets: -101.28%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 12.31
• Quick Ratio: 11.64

Sales & Book Value

• Annual Sales: $10.09 million
• Price / Sales: 27.26
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $31.82 per share
• Price / Book: 1.17

Miscellaneous

• Outstanding Shares: 7,360,000
• Free Float: 7,355,000
• Market Cap: $275.08 million
• Optionable: Not Optionable
• Beta: 2.05